☆ 4.2 Meeting Abstract

CAT-1004, an oral agent targeting NF-κB in development for treatment of Duchenne muscular dystrophy: Phase 1/2 study design

NEUROMUSCULAR DISORDERS (2015)

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

CAT-1004, an oral agent targeting NF-κB in development for treatment of Duchenne muscular dystrophy: Phase 1/2 study design

Rate this paper

Discover Peeref hubs

Find the ideal target journal for your manuscript

Export Citation

Share Paper